Verrica Pharmaceuticals (NASDAQ:VRCA) Given Hold Rating at Needham & Company LLC

Verrica Pharmaceuticals (NASDAQ:VRCA)‘s stock had its “hold” rating restated by stock analysts at Needham & Company LLC in a research report issued on Friday,Benzinga reports.

A number of other equities analysts have also issued reports on the company. TD Cowen cut their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, October 21st. Royal Bank of Canada cut shares of Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $11.00 to $2.00 in a report on Tuesday, November 5th. HC Wainwright downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 6th. Finally, Brookline Capital Management reissued a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.50.

Verrica Pharmaceuticals Price Performance

VRCA opened at $0.69 on Friday. Verrica Pharmaceuticals has a twelve month low of $0.61 and a twelve month high of $11.41. The company has a current ratio of 1.34, a quick ratio of 1.22 and a debt-to-equity ratio of 29.58. The firm has a market cap of $31.66 million, a price-to-earnings ratio of -0.38 and a beta of 1.40. The company has a fifty day simple moving average of $1.11 and a 200 day simple moving average of $3.59.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its earnings results on Monday, November 4th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.12). Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of ($1.78) million for the quarter, compared to analyst estimates of $7.53 million. Equities research analysts expect that Verrica Pharmaceuticals will post -1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several large investors have recently added to or reduced their stakes in VRCA. Barclays PLC increased its stake in Verrica Pharmaceuticals by 404.6% during the third quarter. Barclays PLC now owns 31,341 shares of the company’s stock valued at $45,000 after purchasing an additional 25,130 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Verrica Pharmaceuticals in the 2nd quarter valued at about $50,000. Key Financial Inc bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at about $69,000. Sanctuary Advisors LLC acquired a new stake in Verrica Pharmaceuticals during the third quarter worth about $87,000. Finally, Verition Fund Management LLC acquired a new stake in Verrica Pharmaceuticals during the third quarter worth about $89,000. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.